Inovio Pharmaceuticals

More exciting news from DF/Net client, Inovio Pharmaceuticals.

Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor

PLYMOUTH MEETING, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today a paper published in a major cancer journal detailed results of a patient with head and neck cancer treated with MEDI0457 achieved a sustained complete response (full remission) on treatment with a subsequent PD-1 checkpoint inhibitor. In the Inovio-sponsored study of 22 patients with head and neck squamous cell carcinoma the company reported 91% (20/22) showed T cell activity in the blood or tissue.  MEDI0457­ – formerly called INO-3112 – was in 2015 licensed to MedImmune, the global biologics research and development arm of AstraZeneca. These immune data as well as the financial terms of the license agreement have been previously reported by Inovio. Continue reading on the Inovio website.

DF/Net was the data management and analytics service provider for this study. This was a 100% EDC study with all data entered into the database at site level. DF/Net performed day-to-day study data cleaning utilizing iDataFax reports and edit checks, and served as a liaison between the site, monitors, and client regarding data management issues. MedDRA coding of adverse events was integrated into the database setup and libraries were created, maintained, and updated by DF/Net.

ClientInovio Pharmaceuticals, Inc.